<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575662</url>
  </required_header>
  <id_info>
    <org_study_id>MGH_002</org_study_id>
    <nct_id>NCT04575662</nct_id>
  </id_info>
  <brief_title>Radiotherapy and Atrial Fibrillation</brief_title>
  <acronym>STAR</acronym>
  <official_title>Linac Based STereotactic Arrhythmia Radioablation (STAR) of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miulli General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Miulli General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Current European&#xD;
      guidelines recommend catheter ablation of AF in symptomatic patients refractory to&#xD;
      antiarrhythmic therapy. Pulmonary vein isolation (PVI) remains the cornerstone of any&#xD;
      ablation procedure irrespective of patient characteristics. Recently, stereotactic arrhythmia&#xD;
      radioablation (STAR) with precise high-dose of radiation was used to treat ventricular&#xD;
      arrhythmias in patients with a high risk of complications during transcatheter ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exploratory study to investigate the feasibility of STAR for the treatment of paroxysmal AF&#xD;
      in elderly patients in which a rhythm control strategy is indicated. Patients will be&#xD;
      followed-up for 12 months after STAR treatment for a safety assessment and AF recurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>STAR treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events related to STAR treatment</measure>
    <time_frame>Baseline through 12-months</time_frame>
    <description>To estimate the cumulative proportion of patients' Adverse Events related to STAR treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of AF recurrence</measure>
    <time_frame>Baseline through 12-months</time_frame>
    <description>To estimate the proportion of patients with AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term clinical outcomes</measure>
    <time_frame>Baseline through 10-years</time_frame>
    <description>To estimate the cumulative proportion of all-cause death, cardiovascular death, stroke, heart failure hospitalization, AF recurrence, cancer occurrence</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>STAR Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients performing STAR treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>STAR Treatment</intervention_name>
    <description>Radiation therapy that delivers non-invasive, image-guided, precise high-dose of radiation to targets reducing dose exposure to adjacent normal tissue and minimizing the treatment toxicity.</description>
    <arm_group_label>STAR Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 70 years&#xD;
&#xD;
          2. Symptomatic Paroxysmal AF&#xD;
&#xD;
          3. Antiarrhythmic drugs intolerance or non-response to antiarrhythmic drugs&#xD;
&#xD;
          4. Understands the nature of the study, treatment procedure and provides written informed&#xD;
             consent&#xD;
&#xD;
          5. Willing to comply with specified pre-, post- and follow-up testing, evaluations and&#xD;
             requirements&#xD;
&#xD;
          6. Expected to remain available for at least 24 months after enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Permanent AF&#xD;
&#xD;
          2. Need or wish to continue the intake of restricted medications or any drug considered&#xD;
             likely to interfere with the safe conduct of the trial&#xD;
&#xD;
          3. Unstable angina&#xD;
&#xD;
          4. Presence of any disease that is likely to shorten life expectancy to &lt; 1 year&#xD;
&#xD;
          5. Any cardiac surgery within three months prior to enrolment&#xD;
&#xD;
          6. Awaiting cardiac transplantation or other cardiac surgery within the next year&#xD;
&#xD;
          7. Myocardial infarction (MI) within 60 days prior to enrolment&#xD;
&#xD;
          8. Contraindications to oral anticoagulation&#xD;
&#xD;
          9. Active systemic infection or sepsis&#xD;
&#xD;
         10. Left atrial thrombus (e.g., transesophageal echocardiogram (TEE), CT and ICE)&#xD;
&#xD;
         11. History of a documented thromboembolic event such as stroke or transient ischemic&#xD;
             neurological attack (TIA) in the three months prior to enrollment.&#xD;
&#xD;
         12. Currently enrolled in another trial that has not completed the required follow-up&#xD;
             period and would conflict with this study.&#xD;
&#xD;
         13. Any other clinical condition that might jeopardize patient safety during participation&#xD;
             in this trial or prevent the subject from adhering to the trialprotocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Di Monaco, MD</last_name>
    <phone>+390803054357</phone>
    <email>a.dimonaco@miulli.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Miulli General Hospital</name>
      <address>
        <city>Acquaviva Delle Fonti</city>
        <state>Bari</state>
        <zip>70021</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Di Monaco, MD</last_name>
      <phone>+390803054357</phone>
      <email>a.dimonaco@miulli.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Grimaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alba Fiorentino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Di Monaco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabiana Gregucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Miulli General Hospital</investigator_affiliation>
    <investigator_full_name>Massimo Grimaldi</investigator_full_name>
    <investigator_title>Head of Arrhythmology and Electrophysiology Unit</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Rhythm Control Strategy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

